HPR225 Impact of the 2021 US Federal X-Waiver Practice Guideline Change on the Prescribing of Buprenorphine and Naltrexone for Treating Opioid Use Disorder in Medicaid Population
Dec 1, 2024, 00:00
10.1016/j.jval.2024.10.1649
https://www.valueinhealthjournal.com/article/S1098-3015(24)04512-1/fulltext
Title :
HPR225 Impact of the 2021 US Federal X-Waiver Practice Guideline Change on the Prescribing of Buprenorphine and Naltrexone for Treating Opioid Use Disorder in Medicaid Population
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)04512-1&doi=10.1016/j.jval.2024.10.1649
First page :
Section Title :
Open access? :
No
Section Order :
11113